NiKang Therapeutics is a biotech company focused on discovering and developing innovative small molecules oncology medicines to help patients with unmet medical needs. The company's strategy enables discovery and advancement of proprietary drug candidates with the most desirable pharmacological features into clinical studies.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/26/2021 | Series C | $200MM | $xx.xx | $475.12MM | Cormorant Asset Management, HBM Healthcare Investments, Octagon Capital Advisors, EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavillion Capital, BlackRock, RA Capital Management, Surveyor Capital, Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors, Logos Capital, CBC Group, RTW Investments, Lilly Asia Ventures, Matrix Partners China, Casdin Capital | |
Price per Share
$xx.xx
Shares Outstanding
34,854,728
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Cormorant Asset Management, HBM Healthcare Investments, Octagon Capital Advisors, EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavillion Capital, BlackRock, RA Capital Management, Surveyor Capital, Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors, Logos Capital, CBC Group, RTW Investments, Lilly Asia Ventures, Matrix Partners China, Casdin Capital
|
||||||
09/14/2020 | Series B2 | $5.25MM | $xx.xx | $112.62MM | RTW Investments, Lilly Asia Ventures, Casdin Capital, HBM Healthcare Investments, Matrix Partners China, Octagon Investments, CBC Group | |
Price per Share
$xx.xx
Shares Outstanding
2,083,894
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
RTW Investments, Lilly Asia Ventures, Casdin Capital, HBM Healthcare Investments, Matrix Partners China, Octagon Investments, CBC Group
|
||||||
09/14/2020 | Series B1 | $45MM | $xx.xx | $112.62MM | RTW Investments, Lilly Asia Ventures, Casdin Capital, HBM Healthcare Investments, Matrix Partners China, Octagon Investments, CBC Group | |
Price per Share
$xx.xx
Shares Outstanding
16,071,426
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
RTW Investments, Lilly Asia Ventures, Casdin Capital, HBM Healthcare Investments, Matrix Partners China, Octagon Investments, CBC Group
|
||||||
07/28/2017 | Series A | $10MM | $xx.xx | $15.38MM | CBC Group | |
Price per Share
$xx.xx
Shares Outstanding
10,000,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
CBC Group
|